Bollhagen A, Bodenmiller B
Cancer Discov. 2024; 14(11):2071-2088.
PMID: 39485249
PMC: 11528208.
DOI: 10.1158/2159-8290.CD-23-1165.
Bella A, Arrizabalaga L, Di Trani C, Cirella A, Fernandez-Sendin M, Gomar C
Oncoimmunology. 2022; 11(1):2098657.
PMID: 35859732
PMC: 9291657.
DOI: 10.1080/2162402X.2022.2098657.
Mor A, Strazza M
Front Cell Dev Biol. 2022; 9:790386.
PMID: 35047501
PMC: 8762228.
DOI: 10.3389/fcell.2021.790386.
Li X, Yan S, Yang J, Wang Y, Lv C, Li S
Front Oncol. 2021; 10:574752.
PMID: 33585195
PMC: 7873939.
DOI: 10.3389/fonc.2020.574752.
Simiczyjew A, Dratkiewicz E, Mazurkiewicz J, Zietek M, Matkowski R, Nowak D
Int J Mol Sci. 2020; 21(21).
PMID: 33171792
PMC: 7664679.
DOI: 10.3390/ijms21218359.
Advances in Small-Cell Lung Cancer (SCLC) Translational Research.
Drapkin B, Rudin C
Cold Spring Harb Perspect Med. 2020; 11(4).
PMID: 32513672
PMC: 8015694.
DOI: 10.1101/cshperspect.a038240.
Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F, Aptsiauri N
Immunology. 2019; 158(4):255-266.
PMID: 31509607
PMC: 6856929.
DOI: 10.1111/imm.13114.
Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.
Sivaram N, McLAUGHLIN P, Han H, Petrenko O, Jiang Y, Ballou L
J Clin Invest. 2019; 129(8):3264-3276.
PMID: 31112530
PMC: 6668699.
DOI: 10.1172/JCI123540.
Managing cardiotoxicity associated with immune checkpoint inhibitors.
Upadhrasta S, Elias H, Patel K, Zheng L
Chronic Dis Transl Med. 2019; 5(1):6-14.
PMID: 30993259
PMC: 6450824.
DOI: 10.1016/j.cdtm.2019.02.004.
Association Between the CD28 c.17 +3 T>C Polymorphism (rs3116496) and Cancer Risk: An Updated Meta-Analysis.
Zeng Y, Lai N
Med Sci Monit. 2019; 25:1917-1927.
PMID: 30867406
PMC: 6431111.
DOI: 10.12659/MSM.914677.
Cardiotoxicity of immune checkpoint inhibitors.
Varricchi G, Galdiero M, Marone G, Criscuolo G, Triassi M, Bonaduce D
ESMO Open. 2017; 2(4):e000247.
PMID: 29104763
PMC: 5663252.
DOI: 10.1136/esmoopen-2017-000247.
The association between gene rs3116496 polymorphism and breast cancer risk in Chinese women.
Yan Y, Zhang X
Biosci Rep. 2017; 37(6).
PMID: 29089469
PMC: 5725608.
DOI: 10.1042/BSR20170884.
Immune checkpoint inhibitors in cancer therapy.
Webb E, Liu P, Baleeiro R, Lemoine N, Yuan M, Wang Y
J Biomed Res. 2017; 32(5):317-326.
PMID: 28866656
PMC: 6163118.
DOI: 10.7555/JBR.31.20160168.
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
Boussiotis V
N Engl J Med. 2016; 375(18):1767-1778.
PMID: 27806234
PMC: 5575761.
DOI: 10.1056/NEJMra1514296.
Association between the CD28 IVS3 +17T>C (rs3116496) polymorphism and cancer susceptibility: a meta-analysis involving 8,843 subjects.
Zhang S, Wang Y, Jiang H, Liu C, Gu H, Chen S
Int J Clin Exp Med. 2016; 8(10):17353-61.
PMID: 26770327
PMC: 4694227.
Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.
Hurst J
J Clin Invest. 2015; 125(10):3732-6.
PMID: 26345422
PMC: 4607124.
DOI: 10.1172/JCI84236.
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Buchbinder E, Hodi F
J Clin Invest. 2015; 125(9):3377-83.
PMID: 26325034
PMC: 4588295.
DOI: 10.1172/JCI80012.
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.
Mazzocco M, Martini M, Rosato A, Stefani E, Matucci A, Santa S
Immunology. 2015; 146(1):33-49.
PMID: 25959091
PMC: 4552499.
DOI: 10.1111/imm.12477.
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
Callahan M, Wolchok J
J Leukoc Biol. 2013; 94(1):41-53.
PMID: 23667165
PMC: 4051187.
DOI: 10.1189/jlb.1212631.
Immunomodulatory therapy for melanoma: ipilimumab and beyond.
Callahan M, Postow M, Wolchok J
Clin Dermatol. 2013; 31(2):191-9.
PMID: 23438382
PMC: 3653249.
DOI: 10.1016/j.clindermatol.2012.08.006.